Pathology: mHCC - (neo)adjuvant (NA); mHCC - 1st line (L1); mHCC - 2nd line (L2);
mHCC - (neo)adjuvant (NA) | mHCC - 1st line (L1) | mHCC - 2nd line (L2) | |||||||||||
IMbrave050, 2023 | Wang, 2024 | IMbrave-150, 2020 | COSMIC-312, 2023 | CARES-310, 2023 | EMERALD-1, 2024 | CheckMate 459, 2019 | LEAP 002, 2023 | ORIENT-32, 2021 | RATIONALE 301, 2024 | KEYNOTE-394, 2022 | KEYNOTE-240, 2020 | ||
sintilimab | 2 | T1 | T1 | ||||||||||
atezolizumab plus bevacizumab | 2 | T1 | T1 | ||||||||||
pembrolizumab alone | 2 | T1 | T1 | ||||||||||
durvalumab plus bevacizumab | 1 | T1 | |||||||||||
Tislelizumab | 1 | T1 | |||||||||||
atezolizumab plus cabozantinib | 1 | T1 | |||||||||||
camrelizumab based treatment | 1 | T1 | |||||||||||
pembrolizumab plus lenvatinib | 1 | T1 | |||||||||||
nivolumab alone | 1 | T1 | |||||||||||
Standard of Care (SoC) | 0 | T0 | T0 | ||||||||||
lenvatinib | 0 | T0 | |||||||||||
sorafenib | 0 | T0 | T0 | T0 | T0 | T0 | T0 | ||||||
placebo | 0 | T0 | T0 | T0 |